Pharmaceutical Editorial
  • Home
  • News
  • About
  • Contact

Endo Health Solutions Announces Appointment of Suketu Upadhyay as New Chief Financial Officer

Endo Health Solutions, Medical, Pharmaceuticals, Press Releases

MALVERN, Pa., Sept. 9, 2013 /PRNewswire/ — Endo Health Solutions Inc. (Nasdaq: ENDP), a U.S. based specialty healthcare company, announced today that it had appointed Suketu “Suky” Upadhyay as executive vice president and chief financial officer of Endo, effective September 23, 2013.

“We are delighted to have Suky join the Endo team at this pivotal time,” said Rajiv De Silva, president and chief executive officer of Endo. “He brings significant healthcare industry experience and a track record of delivering value that will be instrumental in the execution of our new growth strategy. His breadth of experience will be an asset to the company as we chart our course forward.”

Prior to joining Endo, Mr. Upadhyay served as principal accounting officer and interim chief financial officer of Becton, Dickinson & Company (BD). In addition to other executive finance roles at BD, he served in various finance leadership roles at Astra Zeneca and Johnson & Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG and received his MBA from The Fuqua School of Business at Duke University.

“I am thrilled to join Endo at such an exciting time,” said Mr. Upadhyay. “The company has made significant progress in transforming its business and is well positioned for its next phase of growth. I look forward to working with Rajiv and the team to shape Endo on its path to become a top tier specialty healthcare company.”

About Endo
Endo Health Solutions Inc. (Endo) is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services, each providing quality products to our customers while improving the lives of patients. Through our operating companies – AMS, Endo Pharmaceuticals, HealthTronics and Qualitest – Endo is dedicated to finding solutions for the unmet needs of patients. Learn more at www.endo.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future” or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo Health Solutions

Related Posts

Medical, Pharmaceutical, Pharmaceuticals, Press Releases

Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting

Allergan, Medical, Pharmaceutical, Pharmaceuticals, Press Releases

Allergan’s Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications

Medical, Pharmaceutical, Pharmaceuticals, Press Releases

The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures

Featured News

  • Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and Outcomes Research 22nd International Meeting
  • Allergan’s Eyepowerment™ Campaign Releases Survey Revealing the Importance of Eye Language and the Crucial Role it Plays in Our Communications
  • The Centers for Disease Control and Prevention Updated Guideline Now Include a Recommendation for Triclosan-Coated Sutures
  • Abbott Announces CE Mark for Tacticath™ Contact Force Ablation Catheter, Sensor Enabled™
  • Abbott Announces CE Mark and First Use of the World’s First SmartPhone Compatible Insertable Cardiac Monitor
Pharmaceutical Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!